Pharmacophore steroid

Denise is registered to practice before the . Patent and Trademark Office. She works closely with clients to maximize effective path to market, especially relating to those products, methods and systems relating to technologies requiring the experienced handling of FDA regulatory compliance issues and trade secret and/or patented technologies in the pharmaceutical, cosmeceutical, nutraceutical, dietary health supplement and medical device product areas. Denise is also admitted to practice in Washington, ., and frequently assists clients in navigating and resolving governmental agency related issues as they arise.

Dutasteride, however, is a so-called dual inhibitor with both 5α-R1 and 5α-R2 inhibition. IC50 for 5α-R1 is 7 nM but 6 nM for 5α-R2. As mentioned above, it reduces DHT > 90% overall, or precisely % and for intraprostatic DHT the reduction is 97-99%. Dutasteride has also been found to inhibit 5α-R3, in vitro, with IC50= nM. [18] The 2,5-difluorophenyl side chain on the D-ring of the compound shows significant lipophilic features and as increased lipophilicity enhances the potency of the compounds binding at pocket site, its potency is much greater than of finasteride. [25]

Pharmacophore steroid

pharmacophore steroid


pharmacophore steroidpharmacophore steroidpharmacophore steroidpharmacophore steroidpharmacophore steroid